Admission levels of soluble CD137 are increased in patients with acute pancreatitis and are associated with subsequent complications

Shao, Zhe; Schäffler, Andréas; Hamer, Okka W.; Dickopf, Judith; Goetz, Andrea; Landfried, Karin; Voelk, Markus; Kopp, Andrea; Herfarth, Hans H; Karrasch, Thomas; Brünnler, T.; Koh, Liang Kai; Buechler, Christa

doi:10.1016/j.yexmp.2011.09.012

Cited by 11 publications

(10 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The increased stimulated 4-1BB response in AH is consistent with that of patients with rheumatoid arthritis [ 14 ]. Also, the levels of s4-1BB in plasma were comparable with the levels found in studies of other inflammatory diseases [ 14 , 25 ] and was not different from concentrations in healthy controls as recently published [ 26 ]. AH is characterized by an overt systemic inflammatory response in combination with vast liver inflammation.…”

Section: Discussionsupporting

confidence: 88%

Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis

et al. 2021

View full text Add to dashboard Cite

Objectives In alcoholic hepatitis (AH), dysfunctional T lymphocytes may contribute to the high mortality from infections. T lymphocyte activation is governed by the expression of co-stimulatory receptors such as 4-1BB balanced by inhibitory receptors such as Programmed Death receptor 1 (PD-1). 4-1BB expression is unaccounted for in AH, while PD-1 is elevated. We characterized expression of 4-1BB and PD-1 and the associated T lymphocyte functional status in AH and investigated whether these were associated with short-term mortality. Methods Thirty-five patients with AH (at diagnosis and days 7 and 90) were compared with healthy controls (HC). Spontaneous and in vitro stimulated receptor expression were quantified by flow cytometry, and plasma proteins by ELISA. Results At diagnosis, the patients showed increased stimulated 4-1BB responses of CD4+ T lymphocytes. Also, the frequencies of PD-1+ T lymphocytes both with and without co-expressed 4-1BB were increased. Further, interferon-gamma was predominantly produced in T lymphocytes co-expressing 4-1BB. A decrease in the frequency of spontaneous 4-1BB+ T lymphocytes and an increase in soluble 4-1BB during the first week after diagnosis were associated with higher mortality at day 90 in AH. PD-1 expression showed no systematic dynamics related to mortality. Conclusions We found an increased stimulated 4-1BB response of T lymphocytes in AH and early loss of these lymphocytes was associated with a higher short-term mortality. This suggests a role of T lymphocyte 4-1BB expression in the progression of AH.

show abstract

Section: Discussionsupporting

confidence: 88%

Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis

et al. 2021

View full text Add to dashboard Cite

show abstract

“…Several groups have demonstrated the association between sCD137 and active inflammatory states in several diseases. For instance, higher levels of sCD137 in patients’ plasma were reported in many autoimmune diseases, acute atherothrombotic stroke, acute coronary syndrome, and acute pancreatitis . In obesity sCD137 was postulated to be a cause of inflammation, and it was shown that inhibiting sCD137 could reverse inflammation .…”

Section: Scd137 Biologymentioning

confidence: 99%

The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention

Luu

Shao

Schwarz

2020

Journal of Leukocyte Biology

Self Cite

View full text Add to dashboard Cite

CD137 is a potent costimulatory receptor. Several agonistic anti‐CD137 antibodies are currently in clinical trials for tumor immunotherapy. Soluble forms of CD137 (sCD137) are generated by differential splicing and antagonize the activities of membrane‐bound CD137 (mCD137) and of therapeutic CD137 agonists. sCD137 is found in sera of patients suffering from autoimmune diseases where it is a natural regulator of immune responses, and which has therapeutic potential for immune‐mediated diseases. This review summarizes the current knowledge on sCD137, highlights its potential role in immunotherapy against cancer and in autoimmune diseases, and presents important issues to be addressed by future research.

show abstract

“…There is some evidence for higher circulating sCD137 levels in patients with different inflammatory diseases [5,22,24]. The sCD137 serum levels of patients with rheumatoid arthritis were greatly increased and were about 20-fold higher in contrast to healthy controls [5].…”

Section: Discussionmentioning

confidence: 99%

“…The serum sCD137 of healthy donors are relatively low, and a pronounced upregulation occurred in the sera of patients with chronic lymphocytic leukemia, autoimmune diseases, or pancreatitis [5,23,24]. The serum sCD137 level of patients with hepatitis C virus and alcohol-related liver cirrhosis also increased [18].…”

Section: Introductionmentioning

confidence: 99%

Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients

Räth,

Mester,

Schwarz

et al. 2023

IJMS

Self Cite

View full text Add to dashboard Cite

T cell depletion and functional impairment are characteristics of sepsis. CD137 is a costimulatory receptor on activated T cells, while soluble CD137 (sCD137) inhibits CD137 signaling. This study found elevated sCD137 levels in the plasma of patients with systemic inflammatory response syndrome (SIRS), sepsis, or septic shock compared to healthy controls. The sCD137 levels negatively correlated with the C-reactive protein and positively with procalcitonin and interleukin-6. There was no difference in sCD137 levels based on ventilation, dialysis, or vasopressor treatment. Patients with SARS-CoV-2, Gram-positive, or Gram-negative bacterial infections had similar sCD137 levels as noninfected individuals. Notably, higher plasma sCD137 levels were observed in non-survivors compared to survivors in both the SIRS/sepsis group and the SARS-CoV-2 subgroup. In conclusion, plasma sCD137 levels are associated with severe illness and survival in critically ill patients.

show abstract

Admission levels of soluble CD137 are increased in patients with acute pancreatitis and are associated with subsequent complications

Cited by 11 publications

References 34 publications

Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis

Early loss of T lymphocyte 4-1BB receptor expression is associated with higher short-term mortality in alcoholic hepatitis

The relevance of soluble CD137 in the regulation of immune responses and for immunotherapeutic intervention

Soluble CD137: A Potential Prognostic Biomarker in Critically Ill Patients

Contact Info

Product

Resources

About